Endocrinology Frontiers

[{"query":"Frontiers in Endocrinology","message_files":[{"filename":"temp6073788989317865846_虚拟基础文章案例2 Frontiers in Endocrinology.docx","type":"document","url":"https://ai.medsci.cn/dev-api/admin-api/infra/file/4/get/3a6bb55252e13dccaf006b5100c8784d313627e69f342c3a758d448f7995747a.docx","size":24550}],"answer":"\n\nExtracted Information:\n\nTitle: Resveratrol ameliorates polycystic ovary syndrome in mice by mitigating ovarian mitochondrial dysfunction and oxidative stress \nJournal: Frontiers in Endocrinology \nAbstract: The study investigates the therapeutic effects of resveratrol on polycystic ovary syndrome (PCOS) using a mouse model. It explores how resveratrol improves ovarian function and systemic metabolic disorders by enhancing mitochondrial biogenesis and reducing oxidative stress, potentially through the SIRT1/PGC-1α/AMPK signaling pathway. \n\nKey Sections: \n1. Introduction: Discusses the prevalence and pathogenesis of PCOS, emphasizing mitochondrial dysfunction and oxidative stress as key contributors. \n2. Materials and Methods: Details the experimental design, including the establishment of a PCOS mouse model, treatment protocols, and analytical methods such as Western blot and qPCR. \n3. Results: Highlights the improvements in body weight, glucose tolerance, ovarian morphology, and hormone levels in resveratrol-treated mice. \n4. Discussion: Explains the mechanisms by which resveratrol ameliorates PCOS, focusing on mitochondrial biogenesis, oxidative stress reduction, and AMPK/mTOR pathway modulation. \n5. Conclusion: Summarizes the therapeutic potential of resveratrol in PCOS treatment. \n\nKeywords: resveratrol, polycystic ovary syndrome, mitochondrial dysfunction, oxidative stress, SIRT1, PGC-1α, AMPK/mTOR \n\nFunding: Supported by National Natural Science Foundation of China, Shanghai Natural Science Foundation, and Key R&D projects in Shanghai. \n\nEthics Statement: Approved by the Laboratory Animal Center of Global Medical University. \n\nAuthor Contributions: Includes data acquisition, analysis, manuscript drafting, and supervision. \n\n---\n\nEvaluation Objective: \nThe document appears to be a scientific article submitted for review to the journal Frontiers in Endocrinology. The primary goal is likely to evaluate its suitability for publication in the journal. \n\n---\n\nClassification Result: \nIn summary, the requirement is classified as "article review". \n\nPlease confirm if the above information is correct. Defaulting to the stated requirement unless further clarification is provided.\n\nThe classification scientist determines that your research type is:\nTranslational Medicine Research\nTranslational Medicine experts are currently reviewing.\n\n### Evaluation Process for Matching the Study to Conversion Medicine Research\n\nTo assess whether the provided study aligns with conversion medicine research, we need to consider several key aspects of the study's methodology, findings, and implications. Conversion medicine, also known as translational medicine, focuses on translating basic science discoveries into practical applications for patient care. Here’s a step-by-step evaluation process:\n\n1. Study Design and Model Selection:\n - Mouse Model: The study uses a well-established mouse model of PCOS induced by letrozole and a high-fat diet. This is a common approach in preclinical research to mimic human conditions.\n - Control Group: The presence of a control group (treated with normal saline) helps in validating the effects of resveratrol.\n\n2. Therapeutic Intervention:\n - Resveratrol Treatment: The study investigates the therapeutic effects of resveratrol, a natural polyphenol, on PCOS. This aligns with the goal of identifying potential therapeutic agents for human diseases.\n\n3. Outcome Measures:\n - Body Weight and Estrous Cycle: Monitoring body weight and estrous cycle in mice provides insights into systemic and reproductive health outcomes, which are relevant to PCOS.\n - Glucose Tolerance and Insulin Sensitivity: These metabolic parameters are crucial in evaluating the systemic effects of resveratrol.\n - Ovarian Morphology and Function: Assessing ovarian morphology and function through histological and molecular biology techniques is essential for understanding the impact on ovarian health.\n\n4. Mechanistic Insights:\n - Mitochondrial Biogenesis and Oxidative Stress: The study explores the role of mitochondrial biogenesis and oxidative stress in PCOS, which are critical factors in ovarian dysfunction.\n - SIRT1/PGC-1α/AMPK Signaling Pathway: Investigating the activation of this signaling pathway provides mechanistic understanding of how resveratrol might work.\n\n5. Statistical Analysis:\n - Two-Way ANOVA and Paired t-test: These statistical methods ensure rigorous analysis of the data, which is crucial for drawing valid conclusions.\n\n6. Relevance to Human Disease:\n - PCOS Prevalence and Pathogenesis: The study addresses a common and complex human disorder, providing potential translational value.\n - Potential Clinical Application: The findings suggest that resveratrol could be a promising therapeutic agent for PCOS, highlighting its potential clinical application.\n\n7. Ethical Considerations:\n - Animal Ethics Approval: The study complies with ethical guidelines for animal experimentation, ensuring the validity and reliability of the results.\n\n8. Author Contributions and Funding:\n - Collaborative Effort: The involvement of multiple authors in data acquisition, analysis, and manuscript drafting indicates a collaborative effort.\n - Funding Sources: The study is funded by reputable sources, including the National Natural Science Foundation of China and the Shanghai Natural Science Foundation, which adds credibility.\n\n### Conclusion\n\nBased on the above assessment, the study clearly aligns with the principles of conversion medicine research. It uses a mouse model to investigate the therapeutic effects of resveratrol on PCOS, providing detailed mechanistic insights into how resveratrol might improve ovarian function and systemic metabolic disorders. The study’s focus on mitochondrial biogenesis and oxidative stress, along with the statistical rigor and ethical considerations, makes it a strong candidate for publication in a journal like Frontiers in Endocrinology.\n\n### Final Classification\n\nThe requirement is correctly classified as "article review" since the study is a scientific investigation aimed at evaluating the therapeutic potential of resveratrol in PCOS, with the intention of contributing to the broader understanding of PCOS and offering new perspectives for its clinical application.\n \n\n\n\nReviewer Report\n\nTo: The Editor, Frontiers in Endocrinology\nFrom: [Reviewer]\nManuscript ID: [Not Provided]\nManuscript Title: "Resveratrol ameliorates polycystic ovary syndrome in mice by mitigating ovarian mitochondrial dysfunction and oxidative stress"\nDate: 2025-08-01\n\nDeclaration: Based on the provided information, this manuscript does not appear to be a previously published article. The following review is based on the assumption that this is a new submission.\n\n***\n\n### Phase 1: Target Journal Analysis\n\n1. Analysis of Similar Articles in Frontiers in Endocrinology\n\nFrontiers in Endocrinology frequently publishes research on the pathophysiology and treatment of Polycystic Ovary Syndrome (PCOS). A review of articles from the past two years shows a strong interest in studies that:\n* Investigate the effects of natural compounds or existing drugs on PCOS phenotypes in animal models.\n* Explore underlying molecular mechanisms, particularly those related to metabolic pathways (e.g., insulin resistance, lipid metabolism), inflammation, and oxidative stress.\n* Combine in vivo data with in vitro validation (often using granulosa cells).\n* Employ standard molecular biology techniques (WB, qPCR, IHC/IF, ELISA) to support phenotypic observations.\n\nThis manuscript's topic and methodology are well-aligned with the journal's scope, particularly within the "Reproductive Endocrinology" section.\n\n2. Journal Preferences and Requirements\n\n* Reviewer Preferences: The journal values methodologically sound research. Clarity in experimental design, reagent sourcing, and statistical analysis is expected.\n* Innovation Requirement: While groundbreaking novelty is not a strict prerequisite, studies should provide a clear contribution to the existing literature. This can include confirming a hypothesis in a more robust model, elucidating a previously suggested but unconfirmed mechanism, or providing a comprehensive dataset that links different pathological aspects.\n* Research Depth: The journal typically expects a clear mechanistic link beyond simple correlation. While multi-level genetic interventions (e.g., KO mice) are not always required, the evidence should strongly support the proposed pathway.\n\n3. Assessment based on BMJ Guidelines\n\n* Importance & Originality: The topic is important, as PCOS is a prevalent disorder with significant metabolic and reproductive consequences. The focus on mitochondrial dysfunction is timely. The originality is moderate; the therapeutic potential of resveratrol in PCOS and its connection to the SIRT1/AMPK pathway have been previously reported. This study's contribution is in providing a consolidated investigation within a letrozole/high-fat diet model, linking systemic metabolic improvements with ovarian-specific molecular changes.\n* Study Design & Methodology: The study uses a relevant animal model and standard techniques. However, there are several points in the design and reporting that require attention (detailed in Phase 2).\n* Ethics & Transparency: The manuscript includes statements on ethical approval for animal experiments, author contributions, and funding, which meets the journal's standards for transparency.\n\n### Phase 2: Overall Review\n\n1. Journal Fit Analysis\n\nThe manuscript is a good fit for Frontiers in Endocrinology. The subject matter, experimental approach, and focus on endocrine and metabolic dysfunction align directly with the journal's scope.\n\n2. Innovation Assessment\n\nThe study provides confirmatory evidence for the role of resveratrol in improving PCOS phenotypes. The primary findings—that resveratrol improves metabolic and ovarian function while modulating the SIRT1/PGC-1α and AMPK/mTOR pathways—are not entirely new. The innovation is limited, as it builds upon existing knowledge rather than presenting a novel discovery. However, the comprehensive evaluation in a combined hyperandrogenism/metabolic syndrome model adds value to the field.\n\n3. Research Value Assessment\n\nThe work has value as a preclinical study that reinforces the therapeutic rationale for using resveratrol in PCOS. It provides a clear dataset that supports the hypothesis that targeting mitochondrial health is a valid strategy for this condition. The findings are relevant to researchers in reproductive endocrinology and metabolism.\n\n4. Methodology Assessment\n\nThe methodology contains several weaknesses that undermine the strength of the conclusions.\n\n* Experimental Groups: A critical control group is missing: a group of healthy control mice treated with resveratrol. Without this group, it is impossible to determine if the observed effects (e.g., weight loss, changes in protein expression) are specific to the reversal of PCOS pathology or are general physiological effects of resveratrol.\n* PCOS Model and Treatment Protocol: The methods state that the PCOS group continued to receive letrozole and a high-fat diet during the 28-day treatment period. This design tests whether resveratrol can prevent or mitigate ongoing damage, not whether it can reverse an established PCOS phenotype. This should be clarified, and the implications of this design on the interpretation of the results must be discussed.\n* Mechanistic Causality: The study demonstrates a correlation between resveratrol treatment and the activation of the SIRT1/PGC-1α/AMPK pathway. It does not establish causation. The conclusion that the mechanism "is mediated through" this pathway is too strong. To support this claim, further experiments would be needed, such as using a specific inhibitor of SIRT1 (e.g., EX-527) in a rescue experiment to show that blocking the pathway negates resveratrol's benefits.\n* Clarity and Accuracy of Methods:\n * The description of reagents is inconsistent and at times vague (e.g., "Keji Biological Company").\n * The description of RNA and protein extraction in sections 2.9 and 2.10 is confusing. It is unclear if a single kit was used for both or if two separate protocols (one with a kit, one with TRIzol) were employed. This must be clarified for reproducibility.\n * The statistical analysis section (2.11) is inaccurate. A comparison of three groups (Control, PCOS, Res) requires a one-way ANOVA with a suitable post-hoc test, not a two-way ANOVA. The use of a "paired t-test" is also not clearly justified in the context of the described group comparisons. The statistical methods must be corrected and described precisely for each experiment.\n* Sample Size: An n of 6 per group is the minimum for animal studies and is susceptible to high variability. While acceptable, this limitation should be acknowledged.\n\n5. Overall Recommendation\n\nMajor Revision.\n\nThe manuscript addresses an important topic and is a good fit for the journal. The data show a clear therapeutic effect of resveratrol. However, the study is weakened by significant issues in the experimental design and a lack of methodological clarity. The conclusions regarding the mechanism are overstated based on the correlational data presented.\n\nTo be considered for publication, the authors must:\n1. Address the missing control group (Control + Resveratrol), either by providing the data or by thoroughly discussing this as a major limitation that tempers all conclusions.\n2. Clarify the experimental design regarding the continued administration of letrozole/HFD during the treatment phase.\n3. Substantially revise the methods section for clarity, detail, and reproducibility, with particular attention to the statistical analysis, which must be corrected.\n4. Tone down the conclusions to reflect the correlational nature of the mechanistic findings (e.g., change "is mediated by" to "is associated with the activation of").\n5. Ideally, provide more direct evidence for the proposed mechanism (e.g., using an inhibitor in vitro or in vivo), which would significantly strengthen the paper.\n\n【--Final content--】\n\n\n Reviewer Report\n\nTo: The Editor, Frontiers in Endocrinology\nFrom: [Reviewer]\nManuscript ID: [Not Provided]\nManuscript Title: "Resveratrol ameliorates polycystic ovary syndrome in mice by mitigating ovarian mitochondrial dysfunction and oxidative stress"\nDate: 2025-08-01\n\nDeclaration: Based on the provided information, this manuscript does not appear to be a previously published article. The following review is based on the assumption that this is a new submission.\n\n***\n\n### Phase 1: Target Journal Analysis\n\n1. Analysis of Similar Articles in Frontiers in Endocrinology\n\nFrontiers in Endocrinology frequently publishes research on the pathophysiology and treatment of Polycystic Ovary Syndrome (PCOS). A review of articles from the past two years shows a strong interest in studies that:\n* Investigate the effects of natural compounds or existing drugs on PCOS phenotypes in animal models.\n* Explore underlying molecular mechanisms, particularly those related to metabolic pathways (e.g., insulin resistance, lipid metabolism), inflammation, and oxidative stress.\n* Combine in vivo data with in vitro validation (often using granulosa cells).\n* Employ standard molecular biology techniques (WB, qPCR, IHC/IF, ELISA) to support phenotypic observations.\n\nThis manuscript's topic and methodology are well-aligned with the journal's scope, particularly within the "Reproductive Endocrinology" section.\n\n2. Journal Preferences and Requirements\n\n* Reviewer Preferences: The journal values methodologically sound research. Clarity in experimental design, reagent sourcing, and statistical analysis is expected.\n* Innovation Requirement: While groundbreaking novelty is not a strict prerequisite, studies should provide a clear contribution to the existing literature. This can include confirming a hypothesis in a more robust model, elucidating a previously suggested but unconfirmed mechanism, or providing a comprehensive dataset that links different pathological aspects.\n* Research Depth: The journal typically expects a clear mechanistic link beyond simple correlation. While multi-level genetic interventions (e.g., KO mice) are not always required, the evidence should strongly support the proposed pathway.\n\n3. Assessment based on BMJ Guidelines\n\n* Importance & Originality: The topic is important, as PCOS is a prevalent disorder with significant metabolic and reproductive consequences. The focus on mitochondrial dysfunction is timely. The originality is moderate; the therapeutic potential of resveratrol in PCOS and its connection to the SIRT1/AMPK pathway have been previously reported. This study's contribution is in providing a consolidated investigation within a letrozole/high-fat diet model, linking systemic metabolic improvements with ovarian-specific molecular changes.\n* Study Design & Methodology: The study uses a relevant animal model and standard techniques. However, there are several points in the design and reporting that require attention (detailed in Phase 2).\n* Ethics & Transparency: The manuscript includes statements on ethical approval for animal experiments, author contributions, and funding, which meets the journal's standards for transparency.\n\n### Phase 2: Overall Review\n\n1. Journal Fit Analysis\n\nThe manuscript is a good fit for Frontiers in Endocrinology. The subject matter, experimental approach, and focus on endocrine and metabolic dysfunction align directly with the journal's scope.\n\n2. Innovation Assessment\n\nThe study provides confirmatory evidence for the role of resveratrol in improving PCOS phenotypes. The primary findings—that resveratrol improves metabolic and ovarian function while modulating the SIRT1/PGC-1α and AMPK/mTOR pathways—are not entirely new. The innovation is limited, as it builds upon existing knowledge rather than presenting a novel discovery. However, the comprehensive evaluation in a combined hyperandrogenism/metabolic syndrome model adds value to the field.\n\n3. Research Value Assessment\n\nThe work has value as a preclinical study that reinforces the therapeutic rationale for using resveratrol in PCOS. It provides a clear dataset that supports the hypothesis that targeting mitochondrial health is a valid strategy for this condition. The findings are relevant to researchers in reproductive endocrinology and metabolism.\n\n4. Methodology Assessment\n\nThe methodology contains several weaknesses that undermine the strength of the conclusions.\n\n* Experimental Groups: A critical control group is missing: a group of healthy control mice treated with resveratrol. Without this group, it is impossible to determine if the observed effects (e.g., weight loss, changes in protein expression) are specific to the reversal of PCOS pathology or are general physiological effects of resveratrol.\n* PCOS Model and Treatment Protocol: The methods state that the PCOS group continued to receive letrozole and a high-fat diet during the 28-day treatment period. This design tests whether resveratrol can prevent or mitigate ongoing damage, not whether it can reverse an established PCOS phenotype. This should be clarified, and the implications of this design on the interpretation of the results must be discussed.\n* Mechanistic Causality: The study demonstrates a correlation between resveratrol treatment and the activation of the SIRT1/PGC-1α/AMPK pathway. It does not establish causation. The conclusion that the mechanism "is mediated through" this pathway is too strong. To support this claim, further experiments would be needed, such as using a specific inhibitor of SIRT1 (e.g., EX-527) in a rescue experiment to show that blocking the pathway negates resveratrol's benefits.\n* Clarity and Accuracy of Methods:\n * The description of reagents is inconsistent and at times vague (e.g., "Keji Biological Company").\n * The description of RNA and protein extraction in sections 2.9 and 2.10 is confusing. It is unclear if a single kit was used for both or if two separate protocols (one with a kit, one with TRIzol) were employed. This must be clarified for reproducibility.\n * The statistical analysis section (2.11) is inaccurate. A comparison of three groups (Control, PCOS, Res) requires a one-way ANOVA with a suitable post-hoc test, not a two-way ANOVA. The use of a "paired t-test" is also not clearly justified in the context of the described group comparisons. The statistical methods must be corrected and described precisely for each experiment.\n* Sample Size: An n of 6 per group is the minimum for animal studies and is susceptible to high variability. While acceptable, this limitation should be acknowledged.\n\n5. Overall Recommendation\n\nMajor Revision.\n\nThe manuscript addresses an important topic and is a good fit for the journal. The data show a clear therapeutic effect of resveratrol. However, the study is weakened by significant issues in the experimental design and a lack of methodological clarity. The conclusions regarding the mechanism are overstated based on the correlational data presented.\n\nTo be considered for publication, the authors must:\n1. Address the missing control group (Control + Resveratrol), either by providing the data or by thoroughly discussing this as a major limitation that tempers all conclusions.\n2. Clarify the experimental design regarding the continued administration of letrozole/HFD during the treatment phase.\n3. Substantially revise the methods section for clarity, detail, and reproducibility, with particular attention to the statistical analysis, which must be corrected.\n4. Tone down the conclusions to reflect the correlational nature of the mechanistic findings (e.g., change "is mediated by" to "is associated with the activation of").\n5. Ideally, provide more direct evidence for the proposed mechanism (e.g., using an inhibitor in vitro or in vivo), which would significantly strengthen the paper.\n\n## Phase 3: Structured Detailed Review Comments ##\n\n### 1. Title\n* Accuracy & Conciseness: The title is generally accurate but makes a causal claim that is not fully supported. The phrase "by mitigating" implies that the mitigation of mitochondrial dysfunction is the proven cause of the amelioration. The data show an association, not proven causality.\n* Suggestion: Change to "Resveratrol Ameliorates Polycystic Ovary Syndrome in Mice and is Associated with Mitigation of Ovarian Mitochondrial Dysfunction and Oxidative Stress." This is more accurate given the correlational nature of the findings.\n\n### 2. Abstract\n* Structure & Completeness: The abstract is well-structured (Background, Methods, Results, Conclusion).\n* Core Results & Logic: The results are summarized clearly.\n* Conclusion Support: The conclusion overstates the mechanistic findings. The phrase "a mechanism potentially mediated through the SIRT1/PGC-1α/AMPK signaling pathway" is better than a definitive statement, but still strong.\n* Suggestion: Revise the last sentence of the conclusion to be more cautious, for example: "Our findings suggest that resveratrol's therapeutic effects are associated with enhanced mitochondrial biogenesis and function, potentially involving the activation of the SIRT1/PGC-1α/AMPK signaling pathway."\n\n### 3. Introduction\n* Background: The background provides a sufficient overview of PCOS, mitochondrial dysfunction, and resveratrol.\n* Scientific Question & Aims: The scientific question and aims are clearly stated.\n* Innovation: The introduction correctly positions the study as an investigation into the specific effects of resveratrol on ovarian mitochondrial function in a PCOS model, which has not been "systematically explored." This is a reasonable claim for the study's contribution. No major issues noted.\n\n### 4. Methods\nThis section requires substantial revision for clarity, accuracy, and reproducibility.\n* Study Design:\n * Major Flaw: A critical control group is missing: Control mice receiving resveratrol. Without this group, it is impossible to know if the observed effects (e.g., weight reduction, SIRT1 activation) are specific to reversing PCOS pathology or are general physiological effects of resveratrol on healthy mice. This is a significant design flaw that must be addressed, at minimum, in the limitations.\n * Model Protocol: The protocol states that the PCOS and Resveratrol groups continued to receive letrozole and a high-fat diet during the 28-day treatment period. This design tests if resveratrol can prevent further damage or mitigate ongoing insults, not if it can reverse an established PCOS condition. The authors should clarify this and discuss its implications. The current interpretation assumes reversal, which is not what was tested.\n* Methodological Rigor & Clarity:\n * Section 2.2 (Reagents): Vague company names like "Keji Biological Company" and "Zhongshan Jinqiao" are not sufficient for reproducibility. Please provide city, state/province, and country for all suppliers. "NDA/RNA/Protein Kit" appears to contain a typo; it should likely be "DNA/RNA/Protein Kit".\n * Section 2.4 (Model): There is a significant error: "The mice in the control group were given a high-fat diet and 1 mg/kg of letrozole...". This describes the PCOS model group, not the control group. This must be corrected. The text says mice were divided into PCOS and Res groups "after successful modeling," but then states the PCOS group continued to receive letrozole/HFD. This is confusing and needs to be stated more clearly as a single, continuous protocol.\n * Section 2.5 (Vaginal Smear): "ultra-fast non-toxic modified Pasteur stain kit" is not a standard term. The standard method is Papanicolaou (Pap) staining or Giemsa staining. Please specify the exact staining method/kit used.\n * Sections 2.9 & 2.10 (WB & qPCR): The description is confusing. Section 2.9 states total protein was collected using a kit. Section 2.10 states RNA was isolated using TRIzol. Was the same ovary sample split and processed with two different methods? Or was a single kit that isolates DNA, RNA, and protein used, followed by a separate TRIzol extraction? This must be clarified.\n* Statistical Analysis (Section 2.11): The description is incorrect.\n * "Two-way analysis of variance (ANOVA) was used to compare the means of multiple samples." For comparing three independent groups (Control, PCOS, Res), a one-way ANOVA followed by a post-hoc test (e.g., Tukey's or Dunnett's) is appropriate. Two-way ANOVA is for analyzing the influence of two different categorical independent variables on one continuous dependent variable.\n * "Statistical analysis of pre and postoperative data in a group was performed using a paired t test." This is appropriate for before-after comparisons within the same group (e.g., body weight), but it needs to be specified exactly where it was used. The description for comparing between groups is incorrect and must be revised.\n* Ethics: The ethics statement is present, which is good. The name "Global Medical University" appears to be a placeholder and should be replaced with the actual institution.\n\n### 5. Results\n* Data Integrity: The presented results seem to follow a logical progression from systemic effects to ovarian morphology and molecular changes.\n* Statistical Accuracy: The interpretation of significance is contingent on the use of correct statistical tests, which, as noted above, are described incorrectly in the methods. The authors must re-evaluate their statistical analysis and report it accurately.\n* Figure Quality: As figures are not provided, I cannot assess their quality. However, the descriptions need clarification. For example, in 3.2, "TP" is used for testosterone. The standard abbreviation is "T". "TP" typically stands for Total Protein. This must be corrected throughout the manuscript and in the figures.\n* Presentation Logic: The flow is logical. However, the interpretation is weakened by the design flaws. For instance, the weight loss in Figure 1A could be a known effect of resveratrol itself, independent of PCOS. Without the Control+Res group, this cannot be concluded as a specific therapeutic effect on PCOS-related obesity.\n\n### 6. Discussion\n* Interpretation: The discussion reasonably interprets the findings but overstates the strength of the mechanistic conclusion. The link between resveratrol, SIRT1/AMPK activation, and improved PCOS phenotypes is presented as a direct causal chain, whereas the data only show a correlation.\n* Comparison with Existing Research: The discussion connects the findings to existing literature on mitochondrial dysfunction in PCOS and the role of SIRT1/AMPK.\n* Limitations: A limitations section is critically absent. The authors must add a detailed paragraph discussing the major limitations:\n 1. The lack of a resveratrol-treated control group.\n 2. The "prevention/mitigation" study design versus a "reversal" design.\n 3. The correlational nature of the mechanistic data and the lack of causal evidence (e.g., from inhibitor studies).\n 4. The small sample size (n=6).\n* Future Outlook: The conclusion about resveratrol's potential is reasonable but should be tempered by the study's limitations.\n\n### 7. References\n* Timeliness & Relevance: The cited references appear relevant.\n* Formatting: The format appears to be a simple numbered list. The authors should ensure it conforms to the specific citation style of Frontiers in Endocrinology.\n\n### 8. Figures & Tables\n* Necessity & Clarity: The described figures (body weight, OGTT/ITT curves, H&E stains, WB/qPCR results) are necessary and standard for this type of study.\n* Legends: Figure legends must be detailed enough to be understood without reading the main text. They must include the statistical test used for comparisons and the exact value of n for each group shown. For example, "Data are presented as mean ± SEM (n=6 per group)."\n* Titles: Titles should be concise and accurate. As noted, abbreviations like "TP" for testosterone must be corrected to "T".\n\n### 9. Point-by-Point Sentence Analysis\n\n* Abstract, Sentence 2: "Mitochondrial dysfunction and the resulting oxidative stress are increasingly recognized as key contributors..." - OK.\n* Abstract, Sentence 7: "...to detect changes in key proteins... as well as the AMPK/mTOR signaling pathway, using Western blot and qPCR." - Awkward phrasing. Suggestion: "...to measure changes in key proteins (SIRT1, PGC-1α, SOD2) and components of the AMPK/mTOR signaling pathway using Western blot and qPCR."\n* Abstract, Conclusion: "Additionally, we explored and found that resveratrol may improve PCOS by enhancing mitochondrial biogenesis..." - The causal link is too strong. Change "by enhancing" to "while enhancing".\n* Section 2.1, Sentence 1: "...reviewed by the Experimental Animal Welfare Ethics Committee of the Experimental Animal Center of Global Medical University..." - "Global Medical University" is likely a placeholder. Replace with the real institution name.\n* Section 2.2, Reagents: "NDA/RNA/Protein Kit (omega)" - Likely a typo for "DNA". Please verify. "Keji Biological Company", "Biyuntian Biotechnology Institute", "Zhongshan Jinqiao" - Insufficient detail. Provide city and country.\n* Section 2.4, Sentence 3: "The mice in the control group were given a high-fat diet and 1 mg/kg of letrozole..." - This is a critical error. This describes the PCOS modeling, not the control group's treatment. This sentence must be corrected to describe the PCOS group. The control group description is correct in the preceding sentence.\n* Section 2.4, Sentence 4: "The mice, after successful modeling, were randomly divided into PCOS group and resveratrol group (n=6)." - This is confusing. It implies there were only two groups after modeling. The control group (n=6) needs to be carried through the entire experiment. The text should clearly state there are three groups in total: Control, PCOS, and PCOS+Resveratrol.\n* Section 2.6, Sentence 1: "...OGTTs were performed repeatedly..." - Vague. Clarify it was performed once after modeling and once after treatment.\n* Section 2.7, Sentence 1: "...ITT experiment on the 21st day of modeling and the 29th day of treatment." - The timing is off. 28 days of treatment would end on day 49 (21+28). An ITT on day 29 of treatment would be day 50. Please clarify the timeline.\n* Section 2.11, Sentence 3: "Two-way analysis of variance (ANOVA) was used..." - Incorrect. This should be one-way ANOVA with a post-hoc test.\n* Section 3.2, Sentence 4: "The serum testosterone (TP) and luteinizing hormone (LH) contents..." - "TP" is the wrong abbreviation for testosterone. Use "T". Correct this throughout the text, figures, and legends.\n* Section 3.3, Sentence 3: "The immunohistochemical and immunofluorescence results of SIRT1 and PGC-1α (Figures 4A, B)..." - The methods section does not describe IHC or IF techniques. This is a major omission. The methods for IHC/IF must be added.\n* Section 3.4, Sentence 1: "WB detected mTOR, p-mTOR, AMPK, and p-AMPK (Figure 5A, D)." - The figure callouts are confusing. Are there two separate blots shown in 5A and 5D? Clarify.\n* Discussion, Sentence 2: "...these beneficial effects are mediated, at least in part, by the mitigation of ovarian mitochondrial dysfunction..." - Overstated. Change "are mediated by" to "are associated with".\n* Conclusion, Sentence 2: "...resveratrol may improve PCOS by enhancing mitochondrial biogenesis..." - As before, change "by enhancing" to "while enhancing" or "in association with enhanced".\n\n### 10. Consistency/Contradiction Assessment\n* Methods vs. Results: The results section (3.3) mentions immunohistochemistry and immunofluorescence, but these techniques are not described in the Methods section. This is a major inconsistency that must be corrected.\n* Introduction vs. Discussion: The background on SIRT1/PGC-1α is introduced in the Introduction and re-explained in the Discussion. While some restatement is normal, the authors should ensure the Discussion focuses on interpreting their specific results in this context, rather than simply repeating background information.\n* Abbreviations: The abbreviation for testosterone ("TP") is incorrect and inconsistent with standard usage ("T").\n\n### 11. Journal Recommendations\nGiven the significant methodological issues (missing control group, flawed statistical description, unclear methods) and the limited novelty, the manuscript is not suitable for Frontiers in Endocrinology (IF ~5.2) in its current form. If the authors cannot provide additional experiments (e.g., the missing control group, inhibitor studies), the work would be better suited for a journal with a focus on solid, albeit confirmatory, preclinical data. The following journals are recommended:\n\n1. Journal of Ovarian Research\n * Impact Factor (2024): ~3.9\n * CAS Partition: Medicine, Q2\n * JCR Partition: Q1 (Reproductive Biology)\n * Review Cycle: ~6-8 weeks\n * Reason: A perfect topical fit. Publishes focused studies on ovarian biology and pathology, including PCOS models. The standard of evidence is appropriate for this work after revision.\n2. Reproductive Biology and Endocrinology\n * Impact Factor (2024): ~3.8\n * CAS Partition: Biology, Q2\n * JCR Partition: Q2 (Reproductive Biology)\n * Review Cycle: ~8-10 weeks\n * Reason: Broad scope covering reproductive science. The study aligns well with its interest in endocrine mechanisms of reproductive disorders.\n3. Gynecological Endocrinology\n * Impact Factor (2024): ~2.1\n * CAS Partition: Medicine, Q4\n * JCR Partition: Q3 (Obstetrics & Gynecology)\n * Review Cycle: ~10-12 weeks\n * Reason: Focuses on the clinical and experimental aspects of gynecological endocrinology. A good outlet for preclinical studies with potential clinical relevance.\n4. Endocrine\n * Impact Factor (2024): ~3.6\n * CAS Partition: Medicine, Q3\n * JCR Partition: Q2 (Endocrinology & Metabolism)\n * Review Cycle: ~4-6 weeks\n * Reason: Covers general endocrinology. The metabolic aspects of this study (insulin resistance, weight) make it a suitable candidate.\n5. Experimental and Therapeutic Medicine\n * Impact Factor (2024): ~2.7\n * CAS Partition: Medicine, Q4\n * JCR Partition: Q3 (Medicine, Research & Experimental)\n * Review Cycle: ~12-14 weeks\n * Reason: Publishes a wide range of experimental studies. The methodological flaws would be more acceptable here after careful revision and discussion in a limitations section.\n6. Molecular Medicine Reports\n * Impact Factor (2024): ~2.8\n * CAS Partition: Medicine, Q4\n * JCR Partition: Q3 (Medicine, Research & Experimental)\n * Review Cycle: ~10-12 weeks\n * Reason: Similar to ETM, focuses on molecular mechanisms of disease. The level of mechanistic evidence presented would be appropriate for this journal.\n\n### 12. User Judgment\nDo you find the above review satisfactory? Are you prepared to revise the article based on these comments? (Please answer "Yes" to proceed to the revision stage, or ask any additional specific questions you may have).\n ","parent_message_id":"00000000-0000-0000-0000-000000000000"}]